Cybin Inc., a leading neuropsychiatry company, recently announced its successful second-quarter results and highlighted key advancements in its clinical trials and global regulatory approvals. With a focus on revolutionizing mental healthcare, Cybin is actively developing new treatment options for conditions like major depressive disorder and generalized anxiety disorder. George Tziras, the chief business officer, will be presenting at the Jefferies Global Healthcare Conference in London to discuss the company's innovative approach to mental health treatments.
Cybin Inc., a leading neuropsychiatry company, will be hosting a conference call to discuss Q2 results and provide updates on their innovative treatment options for mental health disorders. Founded in 2019, Cybin is focused on developing solutions for major depressive disorder and generalized anxiety disorder, operating in multiple countries including Canada, the U.S., the U.K., and Ireland. For more details, visit Cybin's newsroom or explore their breakthrough advancements in mental healthcare.
Cybin Inc., a Phase 3 clinical stage neuropsychiatry company, is set to have their Chief Business Officer speak at the Guggenheim 2nd Annual Healthcare Innovation Conference. The company is dedicated to transforming mental healthcare through the development of novel drugs like CYB003 and CYB004 for major depressive disorder and generalized anxiety disorder, respectively, with the goal of providing effective and lasting treatment options.
Global Psychedelic Week 2025 is the first-ever distributed psychedelic conference, gathering 5,000 participants from 100 countries through a hybrid online and in-person model. With over 100 speakers like Rick Doblin and Robin Carhart-Harris, the event aims to spark global conversations on psychedelic science, therapy, and culture. By hosting in-person gatherings worldwide, GPW fosters a truly global movement from the ground up, promoting local connections and diverse perspectives. Visit www.globalpsychedelicweek.com for registration and early bird discounts.
Cybin Inc., a Phase 3 clinical-stage neuropsychiatry company, will have its Chief Medical Officer, Amir Inamdar, speak at the upcoming 2025 Milken Institute Future of Health Summit in Washington, D.C. The company is dedicated to transforming mental healthcare through innovative treatment options like CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder. Operating in multiple countries since its founding in 2019, Cybin is at the forefront of advancing mental health treatments.
Cybin Inc. has revealed a registered direct offering of common shares and warrants, raising over $175 million in gross proceeds. The offering includes renowned investors and aims to support the development of innovative treatment options for mental health conditions like major depressive disorder and generalized anxiety disorder.
Global Psychedelic Week 2025 offers a diverse program with seven themed days, over 100 events, and 140 speakers from around the world. From scientific discovery to indigenous wisdom, the event explores the evolving landscape of psychedelic research. Visionary voices like Robin Carhart-Harris and Rick Doblin will discuss the fusion of ancient wisdom and modern science. With 5,000 participants from 100 countries, the event aims to unite global communities. Registration is open for virtual and in-person attendance, with scholarships and press accreditation available.
Global Psychedelic Week 2025 will feature 130 global speakers and 100 in-person events worldwide, including discussions on psychedelic therapies in crisis zones, evidence-based approaches in psychedelic enterprises, indigenous perspectives, women in psychedelics, and the role of psychedelics in addressing climate change. The conference aims to decentralize the conversation and prioritize inclusivity and community, with early bird registration discounts available.
NRx Pharmaceuticals, a NASDAQ-listed company, is making strides in the development of preservative-free ketamine-based therapies by refiling an application for KETAFREE and advancing NRX-100 for suicidal ideation in depression. CEO Dr. Jonathan Javitt highlighted new pipeline developments and collaborations, showcasing the company's commitment to bringing these therapies to market.
NRx Pharmaceuticals Inc. has received FDA approval for a Suitability Petition, allowing them to re-file for their preservative-free ketamine product. This aligns with NRx's focus on developing treatments for suicidal depression and PTSD, while tapping into the growing demand for safer pharmaceutical options in the U.S. market.
Global Psychedelic Week 2025, the first distributed psychedelic conference, will bring together 5,000 people from 100 countries with 100+ speakers like Rick Doblin and Robin Carhart-Harris. With events in nearly 60 cities and partnerships with 70+ organizations, GPW aims to promote global dialogue and action on psychedelics. Early bird registration is now open at www.globalpsychedelicweek.com.
Cybin Inc. provided updates on its drug discovery platforms, highlighting key milestones such as upcoming Phase 2 and Phase 3 program data releases for anxiety and depression disorders, along with a strategic manufacturing partnership. The Company's intellectual property portfolio is secured until 2041, with promising response rates and FDA Breakthrough Therapy Designation for its CYB003 program.
Cybin Inc.'s Chief Medical Officer and Chief Business Officer will be participating in a fireside chat at an upcoming summit to discuss the company's focus on developing innovative treatment options for mental health conditions, including their ongoing Phase 3 and Phase 2 studies for major depressive disorder and generalized anxiety disorder, respectively. Established in 2019, Cybin is a clinical-stage neuropsychiatry company with operations in Canada, the United States, the United Kingdom, and Ireland.
NRx Pharmaceuticals' subsidiary HOPE Therapeutics Inc. has acquired Dura Medical, a provider of interventional psychiatry services in Florida, expanding its network. Meanwhile, Cybin Inc. has completed enrollment in its Phase 2 study of CYB004 for Generalized Anxiety Disorder, with topline data expected in Q1 2026, aiming to address the needs of millions of Americans living with GAD.
Cybin Inc., a neuropsychiatry company, will have their Chief Business Officer participating in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference to discuss their focus on developing new treatment options for mental health conditions, including CYB003 in Phase 3 studies for major depressive disorder and CYB004 in a Phase 2 study for generalized anxiety disorder. Established in 2019, Cybin is actively operating in Canada, the United States, the United Kingdom, and Ireland.
Cybin Inc.'s Chief Medical Officer, Amir Inamdar, will be participating in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, discussing the company's focus on developing new treatment options for mental health conditions such as major depressive disorder and generalized anxiety disorder. The session will be webcast live and available for replay on Cybin's investor relations website. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland, aiming to advance mental health solutions.
Cybin Inc. appoints Eric So as Interim CEO following Doug Drysdale's resignation, focusing on advancing clinical pipeline for mental health conditions. Meanwhile, NRx Pharmaceuticals Inc. secures FDA Fast Track designation for IV ketamine formulation NRX-100 in treating suicidal depression, expanding its potential patient pool.
Psylutions, a pioneering cultivator and manufacturer of psilocybin in Colorado, praises the DEA's decision to advance a petition to reschedule psilocybin for scientific review by the U.S. Department of Health and Human Services. This move is seen as a significant stride towards mainstream acceptance of psychedelics in medicine, offering hope for patients in palliative care and Veterans with PTSD. Psylutions is poised to lead the charge in establishing a future where psilocybin therapy is safe, regulated, and easily accessible, emphasizing safety, precise dosing, and collaborative partnerships. Their dedication to legal compliance and patient well-being sets a benchmark for the industry, promising an exciting evolution in psychedelic therapy. Stay updated for further developments on this transformative initiative.
Ketamine Lead Gen partners with HealingMaps and Healing Health Alliance to support the growth of Ketamine & TMS clinics by providing patient education, digital marketing, and operational solutions. The collaboration aims to enhance clinic profitability and scalability through high-intent patient discovery, measurable marketing strategies, and exclusive benefits for clinic owners.
Cybin Inc. has been granted approval to start the EMBRACE Phase 3 study of CYB003 in Australia, marking a significant milestone in their development of new treatment options for mental health conditions. This study is part of Cybin's Phase 3 multinational program, PARADIGM, and focuses on major depressive disorder.